Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Gilead Sciences

    Gilead Sciences () is an American biotechnology company that discovers, develops and commercializes therapeutics.

    Read More at Wikipedia ›

    Related Topics

    1. Vertex Pharmaceuticals
    2. Bristol-Myers Squibb
    3. Abbott Laboratories
    4. Merck
    5. Food And Drug Administration
    6. Pharmaceuticals
    Get updates on Gilead Sciences
    FDA Panel Backs Gilead's HIV 'Quad' Medicine

    A federal advisory panel Friday backed an experimental Gilead Sciences Inc.

    (GILD) HIV medicine known as the Quad.The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.Gilead is hoping that the one-pill, once-daily Quad regimen will p...

    Read More ›

    1. Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies

      Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies.The results unveiled Wednesday co...

    2. WSJ BLOG/Health: Medical Group Blinks Amid Criticism Over Drug-Data Disclosure

      (This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)A European medical society that hosts a major conference ...

    3. European Medical Group Changes Drug Data-Release Policy After Criticism

      A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would...

    4. CORRECT(3/7): Gilead's 'Quad' HIV Drug Is Comparable To Atripla In Study

      ("Gilead's 'Quad' HIV Drug Is Comparable To Atripla In Study," published March 7 at 3:57 pm EST, misstated the rate of discontinuations for adverse events among Quad...

    5. WSJ BLOG/Health: Study of Popular HIV Drug Fuels Prevention Debate

      (This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)The AIDS Healthcare Foundation filed a citizen's petition...

    6. Gilead's 'Quad' HIV Drug Is Comparable To Atripla In Study

      Gilead Sciences Inc.'s (GILD) four-in-one "Quad" tablet was comparable to another combination drug, Atripla, in fighting HIV infection, but with lower rates of certa...

    7. Achillion, Vertex Rally On Gilead's Woes

      Shares of Achillion Pharmaceuticals rallied 23% to $10.77 on Friday after Gilead Sciences ' released disappointing study results for its drug candidate GS-7977, a tr...

    8. Gilead Sinks 15% On Hepatitis C Study

      Shares of Gilead Sciences sank 15% to $46.62 on Friday after the biotech group reported disappointing results from a study for its experimental hepatitis C drug GS-7...

    9. Patients On Gilead's Hepatitis C Drug Relapse In Trial

      Gilead Sciences Inc. (GILD) said a majority of hepatitis C patients in one arm of a clinical trial had a relapse in their disease after being treated with an experim...

    10. Gilead Says Hepatitis C Patients Had Relapse in Trial

      Shares of Gilead Sciences (NASDAQ:GILD) fell 14% Friday morning after the drug maker said a majority of patients enrolled in one of its studies experienced a viral r...

    11. Gilead Shares Gain On Higher Fourth-quarter Profit

      Shares of Gilead Sciences gained on Friday after it reported a healthy rise in quarterly earnings. The biopharmaceutical company late Thursday said its fourth-quarte...

    12. Gilead 4Q Profit Falls Short of Street View

      Gilead Sciences Inc's quarterly profit rose nearly 6 percent as sales at the world's largest maker of HIV drugs increased 11 percent, but costs also rose and the res...

    1. FDA Panel Votes to Support Gilead's HIV Preventer

      A committee of the Food and Drug Administration has given the nod to Gilead Sciences' (NASDAQ:GILD) Truvada drug to help stop the onslaught of HIV infection, putting...

    2. Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

      DOW JONES NEWSWIRESGilead Sciences Inc. (GILD) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though a...

    3. TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

      (This article was originally published Wednesday.)--Janus Global Life Sciences fund has year-to-date return of 14.62%--Manager tries to limit exposure to volatility ...

    4. Gilead, Bristol's Hepatitis C Drugs Show Promise In Study

      A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four wee...

    5. Combination Of Gilead, Bristol-Myers Hepatitis C Drugs Show Promise In Study

      A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four wee...

    6. EARNINGS PREVIEW: US Biotechs' 1Q To Focus On Deals, Pipelines

      TAKING THE PULSE: Investors will likely focus on efforts by large U.S. biopharmaceutical companies to expand their drug pipelines likely as these firms report first-...

    7. Abbott Drugs Suppress Hepatitis C Virus In 2 Studies

      Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies.The results unveiled Wednesday co...

    ‹ Prev123Next ›
    Freebase CC-BY
    Source: Gilead Sciences on Freebase, licensed under CC-BY
    Other content from Wikipedia, licensed under the GFDL